PARLIAMENT QUESTION: INVESTMENT IN ATOMIC RESEARCH FACILITIES

1. At a Glance

• Lok Sabha Unstarred Question answered by Department of Atomic Energy (DAE) on 12 Feb 2026, detailing government investment in expanding nuclear applications in medicine and industry [S1].
• Showcases India's indigenous radiopharmaceutical ecosystem (BARC → BRIT → hospitals) and ties into the broader Nuclear Energy Mission under Budget 2025-26 [S1][S2].
• Relevant for UPSC because it links GS-III (Sci-Tech, nuclear) with GS-II (Health, Parliament) and GS-III (Cancer care, public goods).

2. Why in the News

• Reply tabled in Parliament on 12 Feb 2026 by DAE listing radiopharmaceutical breakthroughs and DAE's cancer-grid investments [S1][S3].
• Comes alongside Union Budget 2025-26's ₹20,000 crore Nuclear Energy Mission for Small Modular Reactors (SMRs) and proposed amendments to the Atomic Energy Act, 1962 and Civil Liability for Nuclear Damage Act, 2010 [S2].

3. Background & Evolution

• DAE established 1954; placed directly under the Prime Minister; functions under Atomic Energy Act, 1962 [S2].
• Bhabha Atomic Research Centre (BARC), Trombay — premier R&D unit; Board of Radiation & Isotope Technology (BRIT) — commercial arm for radioisotope supply [S3].
• National Cancer Grid (NCG) funding by DAE: ₹72 crore (2013-2023), followed by ₹177.05 crore for next 5 years [S3].
• BARC designed India's first PPP Research Reactor for nuclear medicine production (announced 2021) [S3].

4. Core Static Facts

• Implementing Ministry/Dept: Department of Atomic Energy (DAE), under PM directly [S2].
• Enabling Statute: Atomic Energy Act, 1962; Civil Liability for Nuclear Damage Act, 2010 [S2].
• Key Indigenous Radioisotopes / Products [S1][S3]:
• Mo-99 / Tc-99m — diagnostic nuclear medicine
• I-131 — thyroid disorders (diagnosis + therapy)
• I-131 mIBG — high-specific-activity therapeutic dose
• Ga-68-PSMA — prostate cancer detection/staging
• NCA Lu-177 DOTA-TATE / PSMA-617 — cancer therapy
• Cs-137 pencils — blood irradiation
• Ir-192 — brachytherapy
• Ru-106 plaques — ocular tumours
• Y-90 glass microspheres — liver cancer
• Sm-153, I-125 — therapeutic/diagnostic uses
• Nuclear Energy Mission Budget 2025-26: ₹20,000 crore for SMR R&D; target ≥5 indigenous operational SMRs by 2033; 100 GW nuclear capacity by 2047 [S2].

5. Multi-Dimensional Analysis

Scientific / Technological - BARC achieved NCA Lu-177 via extraction-chromatography from 95% enriched Yb-176 targets — a high-purity therapy isotope previously import-dependent [S3]. - Domestic Ga-68-PSMA kits eliminate reliance on cyclotron-imported tracers for prostate cancer [S1].

Social / Public Health - DAE-funded NCG covers >300 cancer centres; ₹177.05 crore allocation deepens equitable access to radiotherapy [S3]. - Indigenous brachytherapy (Ir-192) and Ru-106 plaques cut treatment cost for cervical and ocular cancers [S1].

Economic - Reduces import bill for medical isotopes; positions India as exporter via BRIT [S3]. - ₹20,000 crore SMR allocation signals private-sector entry once Atomic Energy Act is amended [S2].

Legal / Constitutional - Atomic energy in Union List Entry 6 (Schedule VII); amendments to AEA 1962 and CLNDA 2010 pending to allow private/foreign investment [S2].

Strategic - Self-reliant fuel cycle + radiopharma supports Atmanirbhar Bharat and reduces vulnerability to NSG-related supply curbs [S2][S3].

6. Recent Developments (last 12-18 months)

• 12 Feb 2026 — Parliament reply detailing radiopharmaceutical portfolio [S1].
• Feb 2025 — Union Budget 2025-26 launches Nuclear Energy Mission with ₹20,000 cr SMR outlay [S2].
• 2025 — DAE Year-End Review notes scale-up of NCA Lu-177 supply via BRIT [S3].
• Proposed amendments to AEA 1962 and CLNDA 2010 to enable private participation [S2].

7. Prelims Hooks

• DAE functions directly under the Prime Minister, not a Cabinet Minister [S2].
• BRIT (Board of Radiation & Isotope Technology) is DAE's commercial radioisotope supplier [S3].
• Lu-177 PSMA-617 — used for prostate cancer therapy [S1].
• Ga-68-PSMA — used for prostate cancer detection/staging [S1].
• Ru-106 plaques — used for ocular (eye) tumours [S1].
• Y-90 glass microspheres — for liver cancer therapy [S1].
• Cs-137 pencils — used for blood irradiation [S1].
• Tc-99m — workhorse of diagnostic nuclear medicine; parent isotope Mo-99 [S1].
• Nuclear Energy Mission budget outlay: ₹20,000 crore (2025-26) [S2].
• SMR target: 5 indigenous operational SMRs by 2033 [S2].
• Nuclear power capacity goal: 100 GW by 2047 [S2].
• National Cancer Grid DAE funding: ₹72 cr (2013-23) + ₹177.05 cr (next 5 yrs) [S3].
• Atomic energy is Union List Entry 6, Seventh Schedule.
• NCA Lu-177 produced from enriched Yb-176 targets via extraction chromatography [S3].
• BARC designed India's first PPP Research Reactor for medical isotopes [S3].

8. Mains Relevance

• GS-III: Science & Technology — Awareness in fields of IT, Space, Computers, Robotics, Nano-tech, Bio-tech; indigenization of technology.
• GS-II: Health — Issues relating to development & management of Social Sector / Services.
• Plausible question stems: 1. "Discuss the role of the Department of Atomic Energy in expanding India's nuclear medicine ecosystem. How does it complement the National Cancer Grid?" (250 words) 2. "Examine the rationale and implications of the Nuclear Energy Mission announced in Budget 2025-26, including the proposed amendments to the Atomic Energy Act, 1962." (250 words) 3. "India's radioisotope programme is a quiet pillar of Atmanirbhar Bharat. Substantiate." (150 words)

9. Related Topics to Study Next

• Nuclear Energy Mission & SMRs — flagship Budget 2025-26 initiative [S2].
• Civil Liability for Nuclear Damage Act, 2010 — operator liability, supplier clause.
• NSG, IAEA Additional Protocol, India-US 123 Agreement — external nuclear architecture.
• National Cancer Grid (Tata Memorial Centre) — DAE-linked health network [S3].
• Three-Stage Nuclear Programme & Thorium fuel cycle — Homi Bhabha's blueprint.
• AERB (Atomic Energy Regulatory Board) — safety regulator.
• PRIP scheme (Pharma R&D) — synergy with radiopharma manufacture.

10. Common Errors / Trap Areas

• DAE reports to PM, not to Ministry of Science & Technology or MoHFW — frequent confusion.
• BARC vs BRIT vs NPCIL vs AERB — research, commercial supply, power generation, regulator respectively.
• Lu-177 is a therapy isotope; Ga-68 / Tc-99m are diagnostic — swap traps.
• ₹20,000 crore is for the Nuclear Energy Mission / SMRs, not for radiopharma specifically [S2].
• Mo-99 is the parent, Tc-99m the daughter; aspirants often confuse half-lives and roles.

11. Sources

• [S1] PARLIAMENT QUESTION: INVESTMENT IN ATOMIC RESEARCH FACILITIES, PIB, 12 Feb 2026 — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2227084 — (tier 1)
• [S2] Nuclear Power in Union Budget 2025-26 / Nuclear Energy Mission, PIB & India Budget — https://pib.gov.in/PressReleaseIframePage.aspx?PRID=2099244 ; https://www.indiabudget.gov.in/budget2025-26/doc/eb/sbe3.pdf — (tier 1)
• [S3] PARLIAMENT QUESTION: DAE ROLE IN CANCER RESEARCH TREATMENT & DAE Year-End Review 2025, PIB — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2159284 ; https://www.pib.gov.in/PressReleasePage.aspx?PRID=2201302 — (tier 1)